PASSAGE BIO, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PASSAGE BIO, INC. (PASG) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $422.00 thousand for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-09-03
- PASSAGE BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- PASSAGE BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- PASSAGE BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00.
- PASSAGE BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $422.00K.
- PASSAGE BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $20.38M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $0.00 derived: sum of 2 quarters · filed 2026-09-03 | $0.00 derived: sum of 3 quarters · filed 2026-09-03 | $422.00K S-4/A · filed 2026-09-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $422.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $422.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $422.00K 10-Q · filed 2025-05-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $0.00 derived: sum of 2 quarters · filed 2024-03-04 | $0.00 derived: sum of 3 quarters · filed 2024-03-04 | $20.38M 10-K · filed 2024-03-04 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $20.38M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $20.38M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $20.38M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |